Acquisition by Seidel-dugan Cynthia of 79516 shares of Werewolf Therapeutics at 11.55 subject to Rule 16b-3

HOWL Stock  USD 1.59  0.02  1.27%   
About 51% of Werewolf Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Werewolf Therapeutics suggests that many traders are impartial. Werewolf Therapeutics' investing sentiment shows overall attitude of investors towards Werewolf Therapeutics.
  
Filed transaction by Werewolf Therapeutics Officer Chief Scientific Officer. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Acquisition of 79516 stock option (right to buy) at 11.55 of Werewolf Therapeutics by Seidel-dugan Cynthia on 20th of December 2024. This event was filed by Werewolf Therapeutics with SEC on 2022-01-06. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Werewolf Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Werewolf Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Werewolf Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Werewolf Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Werewolf Therapeutics Fundamental Analysis

We analyze Werewolf Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Werewolf Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Werewolf Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash And Equivalents

Cash And Equivalents Comparative Analysis

Werewolf Therapeutics is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Werewolf Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Werewolf Therapeutics stock to make a market-neutral strategy. Peer analysis of Werewolf Therapeutics could also be used in its relative valuation, which is a method of valuing Werewolf Therapeutics by comparing valuation metrics with similar companies.

Peers

Werewolf Therapeutics Related Equities

GLUEMonte Rosa   6.45   
0%
59.0%
CGEMCullinan Oncology   5.94   
0%
54.0%
ACETAdicet Bio   5.81   
0%
53.0%
DSGNDesign Therapeutics   4.34   
0%
40.0%
CELCCelcuity LLC   3.83   
0%
35.0%
STOKStoke Therapeutics   3.36   
0%
31.0%
CCCCC4 Therapeutics   2.60   
0%
24.0%
PASGPassage Bio   1.54   
0%
14.0%
MNOVMediciNova   0.46   
0%
4.0%
ACRVAcrivon Therapeutics,   0.30   
0%
2.0%
EWTXEdgewise Therapeutics   0.06   
1.0%
0%
THRDThird Harmonic   0.37   
3.0%
0%
CSBRChampions Oncology   0.53   
4.0%
0%
MOLNMolecular Partners   1.51   
13.0%
0%
VORVor Biopharma   2.25   
20.0%
0%
IKNAIkena Oncology   3.73   
34.0%
0%
ANEBAnebulo Pharmaceuticals   10.81   
100.0%
0%
When determining whether Werewolf Therapeutics is a strong investment it is important to analyze Werewolf Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Werewolf Therapeutics' future performance. For an informed investment choice regarding Werewolf Stock, refer to the following important reports:
Check out Werewolf Therapeutics Hype Analysis, Werewolf Therapeutics Correlation and Werewolf Therapeutics Performance.
For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.52)
Revenue Per Share
0.082
Quarterly Revenue Growth
(0.86)
Return On Assets
(0.26)
Return On Equity
(0.62)
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.